Neurogene Inc
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
NGNE$26.00+2.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $148,210 | $82,021 |
| Short-term investments | 48,947 | — |
| Prepaid expenses and other current assets | 3,191 | 2,698 |
| Total current assets | 200,348 | 84,719 |
| Property and equipment, net | 17,174 | 20,115 |
| Operating lease right-of-use assets | 3,681 | 4,344 |
| Finance lease right-of-use assets | 98 | 87 |
| Restricted cash | 508 | — |
| Other non-current assets | 764 | — |
| Total assets | $222,573 | $109,265 |
| Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $2,596 | $625 |
| Accrued expenses and other current liabilities | 17,495 | 5,324 |
| Operating lease liabilities, current | 2,559 | 678 |
| Finance lease liabilities, current | 42 | 24 |
| Lease contingent value rights liability, current | 281 | — |
| Total current liabilities | 22,973 | 6,651 |
| Operating lease liabilities, non-current | 12,302 | 3,921 |
| Finance lease liabilities, non-current | 65 | 66 |
| Lease contingent value rights liability, non-current | 1,006 | — |
| Other liabilities | 203 | — |
| Total liabilities | 36,549 | 10,638 |
| Commitments and contingencies (Note 10) | ||
| Convertible preferred stock: | ||
| Series A-1 Convertible Preferred stock, $0.0001 par value; 0 and 18,604,653 shares authorized, issued and outstanding as of December 31, 2023 and 2022, respectively (liquidation value of $40,000 at December 31, 2022) | — | 34,414 |
| Series A-2 Convertible Preferred stock, $0.0001 par value; 0 and 13,291,208 shares authorized, issued and outstanding as of December 31, 2023 and 2022, respectively (liquidation value of $28,675 at December 31, 2022) | — | 28,675 |
| Series B Convertible Preferred stock, $0.0001 par value; 0 and 88,114,739 shares authorized, 0 and 74,405,719 shares issued and outstanding as of December 31, 2023 and 2022, respectively (liquidation value of $181,550 at December 31, 2022) | — | 181,277 |
| Total convertible preferred stock | — | 244,366 |
| Stockholders' equity (deficit) | ||
| Preferred stock, $0.000001 par value; 50,000,000 and 0 shares authorized as of December 31, 2023 and 2022, respectively; 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively | — | — |
| Class A Common stock, $0.0001 par value; 0 and 126,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 0 and 428,334 shares issued and outstanding as of December 31, 2023 and 2022, respectively | — | — |
| Class B Common stock, $0.0001 par value; 0 and 120,010,600 shares authorized as of December 31, 2023 and 2022, respectively; 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively | — | — |
| Common stock, $0.000001 par value; 450,000,000 and 0 shares authorized as of December 31, 2023 and 2022, respectively; 12,823,665 and 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively | — | — |
| Additional paid-in capital | 373,178 | 5,098 |
| Accumulated deficit | (187,154) | (150,837) |
| Total stockholders' equity (deficit) | 186,024 | (145,739) |
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | $222,573 | $109,265 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.